advis0r.com

LNSR

conservative

LENSAR, Inc. · NASDAQ

$5.47
+8.64% · delayed · iex

Snapshot taken 2 hours ago (Aug 3, 2026, 9:06 PM ET). Stored, not recomputed — prices are as of that moment. Open in the app ↗

2025-06-30 → 2026-08-03 · low $5.04 · high $13.26

Analysis AI · anthropic:claude-sonnet-5run Jul 31, 2026, 1:36 PM ET

LENSAR is a small-cap medical device company (ALLY cataract laser system) with improving recurring revenue mix (79% recurring per FY2025 10-K) and modest top-line growth (~12.4% revenue growth per SEC data), but the failed Alcon acquisition (which had valued shares at ~$14+CVR) removed a near-term takeout catalyst and the stock has since deteriorated technically (death cross, bearish trend, RSI 27.5, price down from ~$5.23 to ~$5.03 with a gap down). Balance sheet shows limited cash (~$12.5M) against negative free cash flow (~-$4.3M), giving an estimated ~35 month runway, though continued cash burn and preferred stock terms (NR-GRI Series A) create dilution/financing overhang. Base case is a range-bound, low-conviction name pending clearer evidence of ALLY commercial traction and next earnings print.

Overall
3/100
Confidence
45/100

Catalysts

  • ▲ Q2/Q3 2026 earnings reports could show continued recurring revenue growth from ALLY platform (LNSR:2026-06-01:new_recurring_revenue:5bedcea2)
  • ▲ Analyst commentary (BTIG, Lake Street) reworking profitability models around ALLY platform (LNSR:2026-06-04:cashflow_improvement:25432194)
  • ▲ Potential further international regulatory clearances for ALLY (LNSR:2026-03-31:regulatory_milestone:f8399db7)
  • ▲ Institutional stake disclosures (BlackRock 184,053 shares) suggest some institutional attention (news:news:8d06cef88ebebd7d32511ee4)

Risks

  • ▼ Failed Alcon acquisition removed prior $14/share + CVR takeout premium, creating valuation reset risk (LNSR:2026-06-04:acquisition:a81585c1)
  • ▼ Negative free cash flow (-$4.27M) with limited cash balance ($12.5M) implies ongoing burn and potential need for financing (fund:LNSR:2026-07-31T17:35:40.238Z)
  • ▼ Series A Redeemable Convertible Preferred Stock terms restrict corporate actions and could dilute common shareholders (LNSR:2026-03-31:dilution:8818fdc1, LNSR:2026-03-31:dilution:414da0fa)
  • ▼ Technical picture is weak: death cross, bearish trend, RSI 27.5 (oversold but weak momentum), breakdown flagged, momentum -58% over 120 days (tech:LNSR:2026-07-31T04:00:00Z)
  • ▼ Extensive litigation and IP risk disclosures typical of med-tech sector, plus cybersecurity/ransomware risk factors (LNSR:2026-03-31:litigation:9ae8e4c8, LNSR:2026-03-31:litigation:fa9c73c5)
  • ▼ Very low liquidity/thin trading (avg dollar volume ~$8,135/day) increases price volatility and slippage risk

Scenarios

Bull 20% · Base 50% · Bear 30%

Bull ALLY platform recurring revenue growth accelerates as distributor uncertainty resolves post-merger termination (LNSR:2026-06-01:strategic_partnership:59ae88c5)

Bear Cash burn continues and runway estimate compresses, forcing dilutive equity raise or reliance on restrictive preferred stock terms (LNSR:2026-03-31:dilution:414da0fa)

Missing data

Confirmed forward analyst price targets and estimates (specific figures not in evidence) · Detailed unit sales/ASP trends for ALLY System · Precise upcoming earnings date · Details of any pending litigation outcomes or settlement amounts · Total debt figures (marked n/a in fundamentals) · Insider transaction activity

Technical

Trend
bearish
Tech score
31/100
RSI(14)
45.3
SMA 20/50/200
5.66 / 5.77 / 8.79
MACD
-0.156
ATR(14)
0.168
Rel volume
3.28
Avg $ volume
$10,034.99
Momentum 20/60/120d
-12.1% / 2.8% / -56%
From 52w high
-58.4%
Golden cross
no
Volatility
normal

Fundamentals SEC

Market cap
$66.2M
Shares outstanding
12,104,328
Public float
113,300,000
Revenue
$11.7M
Revenue growth
12.4%
Cash
$12.5M
Debt
—
Runway
35.1 mo

Sources 16

Prices from iex (delayed). Fundamentals from SEC EDGAR. Indicators computed locally. First covered Aug 3, 2026, 9:06 PM ET.